MedTrace Logo

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis

NCT06570291 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 520

Last updated 2025-07-16

No results posted yet for this study

Summary

Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Therapy

Conditions

Interventions

DRUG

Mesenchymal Stem Cells

Allogenic adipose tissue-derived mesenchymal stem cells administrated for intra- articular use

DRUG

Sodium Hyaluronate Injection

Sodium Hyaluronate administrated for intra-articular use

Sponsors & Collaborators

  • Wuxi Cellular Biopharmaceutical Group Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-28
Primary Completion
2026-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06570291 on ClinicalTrials.gov